First a reminder our resident 3-4 bashing team. You guys are so obvious & transparent, it is almost embarrassing.
First of all to declare that shorters have made more $$ than long is 100% speculation.
I kow 3 personal friends, All with string business background. One is an account manager, responsible for portfolios,one million$ & up. He has done quite well, with Onc. Buying in the very low dips & trading out on the spikes.
He is a chart T.A. Guy. That said, he still holds Onc for the longer term.
The oother two, similar stories.
I just don't like when people posts presumptuous theories as if they were true.
Regarding price manipulation? It is being held down. But also well supported.
Not huge volume, by any measure. One exciting day of trading could swing the price wildly, up or down.
What I have noticed?
With the very low volumes, not much corporate buying or selling.
They are standing Pat.
The daily trading patterns are almost identical to each other. A spike @ open. Followed by dips. Then gradual climb upwards through the day.
While we are only talking cents/ share, assuming today closes up. It will be the 9th consecutive uptick for Onc.
That is something not seen in many many months.
The last time I saw a similar pattern, was a few weeks before the A.N. Deal was announced.
Long time ago, same " support" type of pattern.
The price & volume back then was dismal as well.
Moving on to oncolyitics biotech as a company. Some have trouble separating the corporate advancements from the S.P.
The S.P. Regardless of recent developments, is miles away from where it can & should be.
They recently applied for a long awaited phase 3 detail , meeting with FDA.
They went in to say the application was co- authored alongside their pharma co- therapy colleagues.
who knows? There could be a contract sitting waiting for the FDA final directions.?
Either way. Once the parameters have been refined & detailed, they would then need a business development plan to progress into phase 3.
Same story goes for the pancreatic cancer phase 3 trial.
Im not expecting any revelation @ the Q1 update.
before or soon after, absolutely.
The original question, what is holding the price down? Certainly nothing of significant influence.
Same question could ba asked about the price support.
Clinically it is easy to follow.
again, I refer to the company web presentation.
They clearly indicate 4 separate cohorts with Roche Gobblet trial.
3 of which have shown strong evidence to advance. Being either adding additional people, or phase 3 ready.
Just on the 2 arms being MBc & pancreatic cancer, having FDA fast track approval, is ample to justify a corporate value in the billions,as a take over target.
My caution again, to those shorting. Be very careful.
any business announcement would most likely come with a trading hault.
Leaving your ability to cover at great risk.
A business development deal, would immediately move the price well above the $5 range.
A total takeover? Corporate discussed minimum years ago, was one billion $...aka about $12ps.
As notable has clearly identified that number would be in the low side.
We all would be happy to see a take over. That would move the S.P. The quickest & end the shorting games.
Time will tell. & that time is getting closer every day.